Fluorine-18 fluorodeoxyglucose positron emission tomography, gallium-67 scintigraphy, and conventional staging for Hodgkin's disease and non-Hodgkin's lymphoma.

[1]  J. Talbot,et al.  [18F]-FDG positron imaging in clinical management of lymphoma patients. , 2001, Critical reviews in oncology/hematology.

[2]  P. Dupont,et al.  Prognostic value of positron emission tomography (PET) with fluorine-18 fluorodeoxyglucose ([18F]FDG) after first-line chemotherapy in non-Hodgkin's lymphoma: is [18F]FDG-PET a valid alternative to conventional diagnostic methods? , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  S. Reske,et al.  Primary staging of lymphomas: cost-effectiveness of FDG-PET versus computed tomography , 2000, European Journal of Nuclear Medicine.

[4]  J G Morris.  The stage is set for the diffusion of positron emission tomography (PET) in oncology , 1999, The Medical journal of Australia.

[5]  Michael N. Maisey,et al.  Normal variants, artefacts and interpretative pitfalls in PET imaging with 18-fluoro-2-deoxyglucose and carbon-11 methionine , 1999, European Journal of Nuclear Medicine.

[6]  H. Prince,et al.  Current trends in the management of early stage Hodgkin's disease. , 1999, Australian and New Zealand journal of medicine.

[7]  G. Hanks,et al.  Results of the 1988-1989 Patterns of Care Study process survey for Hodgkin's disease. , 1999, International journal of radiation oncology, biology, physics.

[8]  G. Jerusalem,et al.  Whole-body 18F-FDG PET for the evaluation of patients with Hodgkin's disease and non-Hodgkin's lymphoma. , 1999, Nuclear medicine communications.

[9]  K. Yuen,et al.  Mantle irradiation alone for clinical stage I-II Hodgkin's disease: long-term follow-up and analysis of prognostic factors in 261 patients. , 1999, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[10]  R. Fisher,et al.  Chemotherapy alone compared with chemotherapy plus radiotherapy for localized intermediate- and high-grade non-Hodgkin's lymphoma. , 1998, The New England journal of medicine.

[11]  A. Buck,et al.  Whole-body positron emission tomography using fluorodeoxyglucose for staging of lymphoma: effectiveness and comparison with computed tomography , 1998, European Journal of Nuclear Medicine.

[12]  E. Merkle,et al.  Extranodal malignant lymphoma: detection with FDG PET versus CT. , 1998, Radiology.

[13]  S. Reske,et al.  18-F-fluorodeoxyglucose-positron emission tomography as a new approach to detect lymphomatous bone marrow. , 1998, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  J. Ruhlmann,et al.  Functional Imaging of Hodgkin’s Disease with FDG-PET and Gallium-67 , 1998, Nuklearmedizin.

[15]  V. Gebski,et al.  The role of the gallium scan in primary extranodal lymphoma. , 1998, Journal of Nuclear Medicine.

[16]  A. Biggi,et al.  Revisiting the prognostic role of gallium scintigraphy in low-grade Non-Hodgkin’s lymphoma , 1997, European Journal of Nuclear Medicine.

[17]  A. Belakhlef,et al.  False-positive FDG-PET imaging of the thymus of a child with Hodgkin's disease. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[18]  J Kotzerke,et al.  Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging. , 1997, Radiology.

[19]  A. D. Van den Abbeele,et al.  Procedure guideline for gallium scintigraphy in the evaluation of malignant disease. Society of Nuclear Medicine. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[20]  M E Phelps,et al.  Whole-body FDG-PET imaging for staging of Hodgkin's disease and lymphoma. , 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[21]  O. Israel,et al.  The continuing clinical role of gallium 67 scintigraphy in the age of receptor imaging. , 1997, Seminars in nuclear medicine.

[22]  S. Ben-Haim,et al.  Utility of gallium-67 scintigraphy in low-grade non-Hodgkin's lymphoma. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[23]  M. M. Mac Manus,et al.  Is radiotherapy curative for stage I and II low-grade follicular lymphoma? Results of a long-term follow-up study of patients treated at Stanford University. , 1996, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  L. Fuller,et al.  High rate of prolonged remissions following combined modality therapy for patients with localized low-grade lymphoma. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[25]  H. Heimpel,et al.  New diagnostic imaging procedures in Hodgkin's disease. , 1996, Annals of oncology : official journal of the European Society for Medical Oncology.

[26]  B. Glimelius,et al.  Predicting malignancy grade with PET in non-Hodgkin's lymphoma. , 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[27]  O. Israel,et al.  Single-photon emission computed tomography quantitation of gallium citrate uptake for the differentiation of lymphoma from benign hilar uptake. , 1995, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[28]  O. Israel,et al.  The role of Ga-67 scintigraphy in evaluating the results of therapy of lymphoma patients. , 1995, Seminars in nuclear medicine.

[29]  J. Boyages,et al.  The role of high dose 67-gallium scintigraphy in staging untreated patients with lymphoma. , 1994, Australian and New Zealand journal of medicine.

[30]  M. Kaminski,et al.  Imaging of lymphoma with PET with 2-[F-18]-fluoro-2-deoxy-D-glucose: correlation with CT. , 1994, Radiology.

[31]  F. Zunino,et al.  High-dose cisplatin and cyclophosphamide with glutathione in the treatment of advanced ovarian cancer. , 1993, Annals of oncology : official journal of the European Society for Medical Oncology.

[32]  K. Någren,et al.  Uptake of carbon-11-methionine and fluorodeoxyglucose in non-Hodgkin's lymphoma: a PET study. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[33]  S. Minoshima,et al.  The use of FDG-PET in the detection and management of malignant lymphoma: correlation of uptake with prognosis. , 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[34]  D. Mankoff,et al.  Continuous-slice PENN-PET: a positron tomograph with volume imaging capability. , 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[35]  M Tubiana,et al.  Report of a committee convened to discuss the evaluation and staging of patients with Hodgkin's disease: Cotswolds meeting. , 1989, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[36]  C. Bloomfield,et al.  The Non-Hodgkin Lymphoma Pathologic Classification Project. Long-term follow-up of 1153 patients with non-Hodgkin lymphomas. , 1988, Annals of internal medicine.

[37]  P. Stomper,et al.  Planning mantle radiation therapy in patients with Hodgkin disease: role of gallium-67 scintigraphy. , 1988, AJR. American journal of roentgenology.

[38]  G. Canellos,et al.  Residual mass in lymphoma may not be residual disease. , 1988, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[39]  Clifford Goodman,et al.  Society of Nuclear Medicine , 1988 .

[40]  R Paul,et al.  Comparison of fluorine-18-2-fluorodeoxyglucose and gallium-67 citrate imaging for detection of lymphoma. , 1987, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[41]  Gandagule Vn,et al.  Extranodal malignant lymphoma. , 1976 .